Form 4: Virpax Pharmaceuticals Director Gary L. Herman Acquires Stock Options

Director Gary L. Herman of Virpax Pharmaceuticals acquired stock options on July 5, 2024, according to a Form 4 filing with the SEC.

Summary

• Gary L. Herman, a director of Virpax Pharmaceuticals, Inc. (VRPX), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on July 5, 2024.
• Herman acquired 2,500 stock options with an exercise price of $0.578.
• These options vest in full on the twelve-month anniversary of the grant date and expire on July 4, 2034.
• Following the transaction, Herman directly owns 2,500 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding stock option acquisition by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

Form 4, Virpax Pharmaceuticals, Stock Options, Director, VRPX, Gary L. Herman, SEC Filing